Literature DB >> 15589575

Evaluation of germline PTEN mutations in endometrial cancer patients.

Destin Black1, Faina Bogomolniy, Mark E Robson, Kenneth Offit, Richard R Barakat, Jeff Boyd.   

Abstract

BACKGROUND AND
OBJECTIVE: Cowden Syndrome is a rare autosomal dominant disorder characterized by multiple hamartomas, increased risks of breast and thyroid cancers, and possibly endometrial carcinoma. Susceptibility to Cowden syndrome is conferred by germline mutation of the PTEN tumor suppressor gene, and somatic mutations of PTEN are common in sporadic endometrial carcinomas. The aim of this study was to test whether a substantial proportion of endometrial cancers are associated with germline mutations of the PTEN gene, not necessarily in association with clinically overt Cowden syndrome.
METHODS: A retrospective cohort of 240 consecutive patients with pathologically confirmed endometrial carcinoma diagnosed at our institution from 1999 to 2002 was ascertained for study. Genomic DNA was isolated from peripheral blood lymphocytes and the entire PTEN coding region and exon-intron junctions were screened for mutations by single strand conformation polymorphism analysis. Potential variants were subjected to direct sequence analysis.
RESULTS: No clearly deleterious PTEN sequence variant was identified in this screened cohort of endometrial cancer patients. One patient harbored a 5-bp deletion in the intronic region adjacent to the splice acceptor site of PTEN exon 4, but this variant has been previously classified as a rare polymorphism.
CONCLUSIONS: Although these data do not preclude the possibility of an increased risk of endometrial cancer in association with the Cowden syndrome, they indicate that germline PTEN mutations do not account for a significant proportion of genetic attributable risk for endometrial carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15589575     DOI: 10.1016/j.ygyno.2004.09.024

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

Review 1.  The inherited genetics of ovarian and endometrial cancer.

Authors:  Simon A Gayther; Paul D P Pharoah
Journal:  Curr Opin Genet Dev       Date:  2010-04-24       Impact factor: 5.578

Review 2.  Molecular pathogenesis of endometrial and ovarian cancer.

Authors:  Melissa A Merritt; Daniel W Cramer
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 3.  Endometrial cancer gene panels: clinical diagnostic vs research germline DNA testing.

Authors:  Amanda B Spurdle; Michael A Bowman; Jannah Shamsani; Judy Kirk
Journal:  Mod Pathol       Date:  2017-04-28       Impact factor: 7.842

Review 4.  Cowden syndrome: a critical review of the clinical literature.

Authors:  Robert Pilarski
Journal:  J Genet Couns       Date:  2008-10-30       Impact factor: 2.537

Review 5.  Genetics of endometrial cancer.

Authors:  Ayelet Shai; Yakir Segev; Steven A Narod
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

Review 6.  Hereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment?

Authors:  Adele Wong; Joanne Ngeow
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

7.  Screening for germline phosphatase and tensin homolog-mutations in suspected Cowden syndrome and Cowden syndrome-like families among uterine cancer patients.

Authors:  Gerasimos Tzortzatos; Christos Aravidis; Annika Lindblom; Miriam Mints; Emma Tham
Journal:  Oncol Lett       Date:  2015-01-23       Impact factor: 2.967

Review 8.  Genetic basis of Cowden syndrome and its implications for clinical practice and risk management.

Authors:  Amanda Gammon; Kory Jasperson; Marjan Champine
Journal:  Appl Clin Genet       Date:  2016-07-13

9.  Efficacy of liquid-based genetic diagnosis of endometrial cancer.

Authors:  Motoki Matsuura; Kiyoshi Yamaguchi; Masato Tamate; Seiro Satohisa; Mizue Teramoto; Masahiro Iwasaki; Shintaro Sugita; Tadashi Hasegawa; Rika Koubo; Kiyoko Takane; Tsuneo Ikenoue; Yoichi Furukawa; Tsuyoshi Saito
Journal:  Cancer Sci       Date:  2018-10-26       Impact factor: 6.716

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.